Images List Premium Download Classic

Immune Response

Immune Response-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Bacterial minicells for delivering nucleic acid adjuvants and methods of using the same
Engenelc Molecular Delivery Pty. Ltd.
April 12, 2018 - N°20180100159

This disclosure provides intact bacterially derived minicells containing nucleic acids adjuvants or plasmids encoding nucleic acids adjuvants that can produce a desired immune response in target cells. This disclosure further provides methods that employ minicells to deliver nucleic acids adjuvants for use in the treatment of diseases, including neoplastic disease and cancer.
Novel peptides and combination of peptides for use in immunotherapy against various tumors
Immatics Biotechnologies Gmbh
April 12, 2018 - N°20180100005

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated t-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor ...
Lymph node-targeting nanoparticles
Duke University
April 12, 2018 - N°20180099044

Provided are nanoparticles comprising heparin, chitosan, and at least one immunomodulatory agent, e. G. A cytokine. The cytokine can be selected from the group consisting of tnf, il-12, il-2, il-23, il-1α, il-10, il-18, and combinations thereof. Further provided are methods of making a nanoparticle comprising mixing a first composition comprising heparin with a second composition comprising chitosan in ...
Immune Response Patent Pack
Download 464+ patent application PDFs
Immune Response Patent Applications
Download 464+ Immune Response-related PDFs
For professional research & prior art discovery
inventor
  • 464+ full patent PDF documents of Immune Response-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Anti-fugetactic agents for the treatment of cancers
The General Hospital Corporation
April 12, 2018 - N°20180099037

This invention provides methods and compositions for modulating movement of eukaryotic cells with migratory capacity. More specifically, the invention provides anti-fugetactic agents and methods for the use thereof in enhancing an immune response.
Antifugetactic agents for the treatment of cancers
The General Hospital Corporation
April 12, 2018 - N°20180099036

This invention provides methods and compositions for modulating movement of eukaryotic cells with migratory capacity. More specifically, the invention provides antifugetactic agents and methods for the use thereof in enhancing an immune response.
Antifugetactic agents for the treatment of cancers
The General Hospital Corporation
April 12, 2018 - N°20180099035

This invention provides methods and compositions for modulating movement of eukaryotic cells with migratory capacity. More specifically, the invention provides anti-fugetactic agents and methods for the use thereof in enhancing an immune response.
Immune Response Patent Pack
Download 464+ patent application PDFs
Immune Response Patent Applications
Download 464+ Immune Response-related PDFs
For professional research & prior art discovery
inventor
  • 464+ full patent PDF documents of Immune Response-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Vaccine compositions and methods of use thereof
University Of Miami
April 12, 2018 - N°20180099032

Nanoparticle-based vaccines, compositions, kits and methods are used for the effective delivery of one or more antigens in vivo for vaccination and antibody (e. G., monoclonal antibody) production, and for the effective delivery of peptides, proteins, sirna, rna or dna to papcs or mhc class ii positive cells (e. G. Tumor cells). Antigens may be, for example, dna that results ...
Compositions and methods for preventing tumor growth and treating cancer by targeting lectin galactoside-binding soluble 3 ...
Bioxcel Corporation
April 05, 2018 - N°20180094058

The present invention discloses a method of treating, preventing or ameliorating tumor growth by immune response modulation via targeting lgals3bp-cd33 related siglec pathway using antibody or antibody-drug conjugate therapy. The present invention also provide use of anti-lgals3bp antibody in combination with an immune checkpoint inhibitor for enhancing, increasing, promoting, expressing, modulating desirable immune response for prevention and treatment ...
Mosaic chimeric viral vaccine{[s]] particle
The Texas A&m University System
April 05, 2018 - N°20180094046

The present invention describes compositions and methods for priming protective immunity in the presence of pre-existing maternal antibody. In some embodiments, the invention contemplates simultaneously masking vaccines to avoid antibody neutralization while targeting those vaccines to specific cell types in order to elicit an enhanced immune response. In other embodiments, vectors that recruit and activate specific antigen-presenting cells may further ...
Novel peptides and combination of peptides for use in immunotherapy against various tumors
Immatics Biotechnologies Gmbh
April 05, 2018 - N°20180094043

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated t-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor ...
Methods and reagents to treat autoimmune diseases and allergy
April 05, 2018 - N°20180092983

The present invention provides compositions for inducing immune tolerance and methods to modify antigen to treat disease such as autoimmune diseases and allergy. Disclosed are compositions, and related methods, comprising apc presentable antigens and immunosuppressants that provide tolerogenic immune responses specific to antigen. In some embodiments, the composition is used for transdermal delivery.
Methods and compositions for affecting immunological responsiveness
Cellprint Ip Holding, Llc
April 05, 2018 - N°20180092973

A method of treating a subject having a deficient immune response is described. The method includes administering a therapeutically effective amount of non-immune drug, or an analog or metabolite thereof, known to induce one or more autoimmune syndromes to the subject. Drugs known to induce one or more autoimmune syndromes, such as lupus-like syndromes, include immune checkpoint inhibitor blockers. Methods ...
Modulators of myc, and methods of using the same
Taiga Biotechnologies, Inc.
April 05, 2018 - N°20180092972

Disclosed herein are methods of modulation of the viability of a cell. Further disclosed herein are methods of modulating an immune response. Further disclosed herein are methods of identifying agents capable of modulation of the viability of a cell or an immune response. Further disclosed herein are agents and compositions capable of modulation of the viability of a cell or ...
Immune Response Patent Pack
Download 464+ patent application PDFs
Immune Response Patent Applications
Download 464+ Immune Response-related PDFs
For professional research & prior art discovery
inventor
  • 464+ full patent PDF documents of Immune Response-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Small molecule enhancer for dendritic cell cancer vaccines
Trustees Of Tufts College
April 05, 2018 - N°20180092933

Disclosed is a method of treating cancer, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound that inhibits a plurality of mammalian dash serine proteases. Also disclosed is a method of (a) increasing antitumor immunity, (b) stimulating or enhancing an immune response, (c) treating a condition characterized by abnormal cell proliferation, (d) increasing cytokine ...
Thermostable vaccine compositions and methods of preparing same
Soligenix, Inc.
April 05, 2018 - N°20180092851

Compositions relating to thermostable vaccines and methods of preparing same. Specifically, methods of preparing thermostable vaccines based on a recombinant ricin neurotoxin protein and uses of co-adjuvants to develop a composition capable of eliciting an immune response in a subject.
Methods and products for evaluating an immune response to a therapeutic protein
Biogen Ma Inc.
March 29, 2018 - N°20180088127

The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. Aspects of the invention relate to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a vla4 binding antibody (e. G., natalizumab).
Cytomegalovirus vectors enabling control of t cell targeting
March 29, 2018 - N°20180087069

Cmv vectors comprising a heterologous protein antigen, an active ul131 protein (or an ortholog thereof), and an active ul128 protein (or an ortholog thereof) but lacking an active ul130 protein (or an ortholog thereof) are provided. Cmv vectors comprising a heterologous protein antigen, an active ul131 protein (or an ortholog thereof), and an active ul130 protein (or an ortholog thereof) ...
Method for reducing the immune response to a biologically active protein
Affibody Ab
March 29, 2018 - N°20180086822

A new use of a molecule comprising at least one moiety which is a biologically active protein and at least one moiety capable of binding to a serum albumin of a mammal is provided, for preparation of a medicament which elicits no or a reduced immune response upon administration to the mammal, as compared to the immune response elicited upon ...
Mutated salmonella enterica
The United States Of America, As Represented By The Secretary Of Agriculture
March 29, 2018 - N°20180086794

A novel, mutated salmonella enterica serovar typhimurium vaccine is generated and imparts protective immunity in vaccinated animals for a range of s. Enterica serovars. The vaccine can be attenuated or inactivated, including bacterial ghosts or membrane fractions thereof. Immunogenic compositions are included in the invention and methods of generating an immune response.
Vaccines with cd40 ligand as an adjuvant
Inovio Pharmaceuticals, Inc
March 29, 2018 - N°20180085451

Disclosed herein is a vaccine comprising an antigen and cd40l. Also disclosed herein are methods for increasing an immune response in a subject. The methods may comprise administering the vaccine to the subject in need thereof.
Immunogenic fusion proteins for the treatment of cancer
The Johns Hopkins University
March 29, 2018 - N°20180085446

Provided herein are compositions and methods for eliciting an immune response in a subject. In particular, the present disclosure is directed to immunogenic fusion proteins and methods of eliciting an immune response using host cells comprising nucleic acid molecules encoding said fusion proteins.
Loading